what is in semaglutide compound | C187H291N45O59 | CID 56843331 FDA alerts health care providers,
Description
But some patients notice something unexpected during their weight loss journey: New or worsening back pain
Originally designed for diabetes management, GLP-1/GIP medications help regulate blood sugar levels by enhancing insulin production and reducing glucose spikes
The American Diabetes Association Standards of Care advises caution when using these agents in patients with gastroparesis
It is important to note that all dosing regimens described here are investigational
The safety profile is well-characterized and generally favorable when used according to prescribing guidelines
The average difference in weight loss for the lowest dose of Mounjaro compared to the control group was 12%
